The case for bladder botulinum toxin application.
Botulinum toxin (BoNT) has been shown to be and effective agent in suppressing detrusor overactivity due to neurogenic causes. Recently, BoNT has been extended to patients who have idiopathic detrusor overactivity. This article reviews the use of BoNT to treat disorders of neurogenic detrusor overactivity and establishes BoNT as a therapeutic modality to treat idiopathic bladder overactivity. It is important to remember that the application of BoNT in the lower urinary tract is not approved by the regulatory agencies and caution should be applied until larger randomized clinical studies are completed.
Kim
Dae Kyung
DK
Department of Urology, Eulji University School of Medicine, 1306 Dunsandong Seogu, Daejeon, Korea.
Thomas
Catherine A
CA
Smith
Christopher
C
Chancellor
Michael B
MB
D000283:Administration, Intravesical; D001905:Botulinum Toxins / Q000008:administration & dosage; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D006801:Humans; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D009465:Neuromuscular Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A